October 18, 2022

Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022

Press Release

PARSIPPANY, N.J.–Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current antibiotic portfolio at Infectious Disease Week (IDWeek) 2022, taking place October 19– 22, 2022, in Washington, D.C. Additionally, new rezafungin clinical and preclinical data will be presented in six poster presentations. As previously announced, Melinta has licensed the U.S. commercial rights to rezafungin, an investigational candidate currently under FDA review, from Cidara Therapeutics.

IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).

Details of the presentations are provided below. The complete program of titles and abstracts can be accessed on the IDWeek 2022 website at www.idweek.org.

Melinta Portfolio Poster Presentations

Product	Title	Poster Number	Date
Meropenem-Vaborbactam	Activity of Novel β -Lactam/ β -Lactamase Inhibitor (BL/BLI) Combinations Against AmpC-Producing Species Collected in United States Hospitals	Poster 124	Thursday, October 20, 2022; 12:15 – 1:30 PM
Meropenem-Vaborbactam	Frequency of Carbapenemases in United States Hospitals (2016-2020) and Activity of Meropenem-Vaborbactam and Comparator Agents Tested Against These Isolates	Poster 126	Thursday, October 20, 2022; 12:15 – 1:30 PM
Oritavancin	Oritavancin Activity Against Gram-positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units in US Medical Centers (2010-2019)	Poster 430	Thursday, October 20, 2022; 12:15 – 1:30 PM
Meropenem-Vaborbactam	Activity of Meropenem-Vaborbactam and Comparators Against Isolates from Patients in Hematology/Oncology and Transplant Units in the United States	Poster 644	Thursday, October 20, 2022; 12:15 – 1:30 PM
Minocycline for Injection	Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014-2021	Poster 645	Thursday, October 20, 2022; 12:15 – 1:30 PM
Oritavancin	Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)	Poster 646	Thursday, October 20, 2022; 12:15 – 1:30 PM
Delafloxacin	In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)	Poster 2176	Saturday, October 22, 2022; 12:15 – 1:30 PM
Minocycline for Injection	Mortality Associated with Stenotrophomonas maltophilia Bloodstream Infection In Patients With Leukemia	Poster 1844	Saturday, October 22, 2022; 12:15 – 1:30 PM
Oritavancin	Oritavancin Compared to the Standard-of-Care for the Treatment of Gram-positive Blood Stream Infections	Poster 1845	Saturday, October 22, 2022; 12:15 – 1:30 PM

Rezafungin Poster Presentations

Product	Title	Poster Number	Date
Rezafungin	Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis	Poster 231	Thursday, October 20, 2022; 12:15-1:30 PM
Rezafungin	Assessment of The Proportion of Hospitalized Patients with Candidemia and Invasive Candidiasis without Candidemia Who Received an Echinocandin and Were Potentially Eligible for an Earlier Hospital Discharge	Poster 468	Thursday, October 20, 2022, 12:15 – 1:30 PM
Rezafungin	Healthcare Resource Utilization among Hospitalized Patients with Candidemia and Invasive Candidiasis without Candidemia Who Received Definitive Treatment with an Echinocandin Across United States (US) Hospitals	Poster 469	Thursday, October 20, 2022, 12:15 – 1:30 PM
Rezafungin	Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)	Poster 592	Thursday, October 20, 2022, 12:15 – 1:30 PM
Rezafungin	Coadministration of Rezafungin Does Not Impact the Pharmacokinetics of Cyclosporine, Ibrutinib, Mycophenolate Mofetil, or Venetoclax	Poster 1694	Saturday, October 22, 2022; 12:15 – 1:30 PM
Rezafungin	Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021	Poster 1731	Saturday, October 22, 2022; 12:15 – 1:30 PM

About Melinta Therapeutics

Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes six commercial-stage products: Baxdela® (delafloxacin), Kimyrsa® (oritavancin), Minocin® (minocycline) for Injection, Orbactiv® (oritavancin), TOPROL-XL® (metoprolol succinate) and Vabomere® (meropenem and vaborbactam). Melinta also has a licensing agreement in place with Cidara Therapeutics securing the rights to market and distribute development candidate rezafungin in the United States.

With an unsurpassed commitment to providers and the patients they serve, Melinta works to ensure that all people who need their therapies can receive them. Melinta focuses its expanding portfolio on serving patients with an unmet need to make the most meaningful impact. Melinta is dedicated to innovation while staying grounded in what matters most: patients. For additional information regarding Melinta’s products, including product indication and important safety information, please visit our website at https://melinta.com.

For additional information regarding Cidara Therapeutics and rezafungin, please visit https://www.cidara.com/.

TOPROL-XL® is a registered trademark of AstraZeneca Pharmaceuticals LP and is used with permission.

← Prev Next →

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.